Лечение артериальной гипертензии при менопаузальном метаболическом синдроме: осталось ли место для β-адреноблокаторов?

1. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Рос. кардиол. журн. 2006; 4: 45–50.
2. Ezzati M, Lopez AD, Rodgers A et al. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360 (9343): 1347–60.
3. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension 2001; 37: 1199–208.
4. August P, Oparli S. Hypertension in women. J Clin Endocr Metab 1999; 84 (6): 1862–6.
5. The therapeutic challenge in postmenopausal hypertension. Ed. By A. Pines. Berlin, New York: de Greuter, 2000. 52 p.
6. Staessen J, Bulpit CJ, Fagard R et al. The influence of menopause on blood pressure. J Hum Hypert 1989; 3: 427–33.
7. Staessen J, Ginocchio G, Thijs L, Fagard R. Conventional and ambulatory blood pressure and menopause in a prospective population study. J Hum Hypert 1997; 11: 507–14.
8. Wassertheil-Smoller S, Anderson G, Psaty B et al. Hypertension and it's treatment in postmenopausal women: baseline data from Women's Health Initiative. Hypertension 2000; 36: 780–9.
9. Лазебник Л.Б., Комиссаренко И.А., Милюкова О.М. Артериальная гипертония у пожилых. М.: Изд-во МАИ, 2003.
10. Wilhelmsen L, Bengtsson C, Elmfeldt D et al. Multiple risk prediction of myocardial infarction in women as compared with men. Brit Heart J 1977; 39: 1179–85.
11. Manolio T, Kronmal R, Burke G et al. Short-term predictors of incident stroke in older adults. The Cardiovascular Health Study. Stroke 1996; 27 (9): 1479–86.
12. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997; 18 (10): 1569–82.
13. Taylor R, Corconre A, Page I. Menopausal hypertension: a critical study. Am J Med Sci 1947; 213: 475–6.
14. Posner B, Cupples L, Miller D et al. Diet, menopause and serum cholesterol levels in women: the Framinham Study. Am Heart J 1993; 125: 483–9.
15. Schillaci G, Verdecchia P, Borgioni C et al. Early cardiac changes after menopause. Hypertension 1998; 32: 764–9.
16. Подзолков В.И., Подзолкова Н.М., Можарова Л.Г., Хомицкая Ю.В. Артериальная гипертензия у женщин в пери- и постменопаузе. В кн.: Медицина климактерия. Ред. В.П.Сметник. М.: Литтерра, 2006.
17. Брагина А.Е. Роль дифференцированной заместительной гормональной терапии в лечении артериальной гипертензии у женщин в перименопаузе. Автореф. дис. … канд. мед. наук. М., 2000.
18. Баранова Е.И. Гипертоническая болезнь у женщин в постменопаузе: особенности клинических проявлений, патогенеза и лечения. Автореф. дис. … д-ра мед. наук. СПб., 1998.
19. Sung B, Ching M, Izzo J et al. Estrogen improves abnormal norepinephrine-induced vasoconstriction in postmenopausal women. J Hypertens 1999; 17 (4): 523–8.
20. Spencer C, Godsland I, Stevenson J. Is there a menopausal metabolic syndrome? Gynecol Endocrinol 1997; 11: 341–5.
21. Carr M. The emergence of metabolic syndrome with menopause. J Clin Endocrinol Metab 2003; 88: 2404–11.
22. Walton C, Godsland I, Proudler A et al. The effects of menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women. Eur J Clin Invest 1993; 23: 466–73.
23. Быстрова М.М., БритовА.Н., Горбунов В.М. и др. ЗГТ у женщин с артериальной гипертонией в пери- и постменопаузе: гемодинамические эффекты. Тер. арх. 2001; 73 (10): 33–8.
24. Colditz GA, Hankinson SE, Hunter DJ et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589–93.
25. Сметник В.П., Шестакова И.Г. Менопауза и сердечно-сосудистая система. Тер. арх. 1999; 71 (10): 61–5.
26. Барт Б.Я., Бороненков Г.М., Беневская В.Ф. Артериальная гипертония у женщин в постменопаузе: современные возможности медикаментозной терапии в поликлинических условиях. Рос. кардиол. журн. 2001; 5: 69–70.
27. Rosental T, Oparil S. Hypertension in women. J Hum Hypertens 2000; 14: 691–704.
28. Kotchen JM, Kotchen TA. Impact of female hormones on blood pressure: review of potential mechanisms and clinical studies. Curr Hypertens Rep 2003; 5: 505–12.
29. Vilecco AS, de Aloyso D, Radi D et al. Plasma catecholamines in pre- and postmenopausal women with mild to moderate essential hypertension. J Hum Hypertens 1997; 11: 152–62.
30. Мануилова И.А. Клиника, патогенез и лечение посткастрационного синдрома. М., 1980.
31. Vongpatanasin W, Tuncel M, Mansour Y et al. Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women. Circulation 2001; 103: 2903–8.
32. Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов (третий пересмотр). Кардиоваскул. тер. и профилак. 2008; 7 (6): 32.
33. Messerli F, Grossman E, Golbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279 (23): 1903–7.
34. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364: 1684–9.
35. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as rquired, in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.
36. Lindholm LH, Carlberg B, Samuelsson O. Should b blockers remain the first choice in the treatment of primary hypertension? A meta-analisis. Lancet 2005; 366: 1545–53.
37. Psaty BM, Smith NS, Siscovick DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997; 277: 739–45.
38. Aursnes I, Osnes JB, Tvete IF et al. Does atenolol differ from other b-adrenergic blockers? BMC Clin Pharmacology 2007; 7: 4.
39. Wiysonge C, Bradley H, Mayosi B et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007; 1): CD002003.
40. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335–71.
41. Freemantle N, Cleland J, Young P et al. Beta blockade after myocardial infarction. Systematic review and meta regression analysis. BMJ 1999; 1730–7.
42. Еblad B, Bjurо T, Bjоrkman J-A et al. Role of central nervous β-adrenoceptors in the prevention of ventricular fibrillation through augmentation of cardiac vagal tone. J Am Coll Cardiol 1991; 17: 1A-65.
43. Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of trearment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur Heart J 1987; 8: 103–13.
44. Buhtel FR, Berglund G, Anderson OK et al. Smoking status and cardioselective beta-blockade antihypertensive therapy: the Bisoprolol International Multicentre Study (BIMS). J Hypertens 1986; 4: 144–6.
45. Amabile G, Serradimigni A. Comparison of bisoprolol with nifedipine for treatment of essential hypertension in the elderly: comparative double–blind trial. Eur Heart J 1987; 8 (Suppl. M): 65–9.
46. Breed J, Ciampricotti R, Tromp G et al. Quality of life perception during antihypertensive treatment: a comparative study of bisoprolol and enalapril. J Cardiovasc Pharmacol 1992; 20: 750–5.
47. Gosse P, Roudaut R, Herrero G, Dallocchio M. Beta-blockers vs angiotensin–converting enzyme inhibitors in hypertension: effects of left ventricular hypertrophy. J Cardiovasc Pharmacol 1990; 16 (suppl. 5): 145–50.
48. Khan N, McAlister F. Re-examining the efficacy of b-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006; 174 (12): 1737–42.
49. Neutel J, Smith D, Rum C et al. Comparison of bisoprolol with atenolol for systemic hypertension in four population groups (young, old, black and nonblack) using ambulatory blood pressure monitoring. Bisoprolol Investigators Group. Am J Cardiol 1993; 72 (1): 41–6.
50. Elliott WJ , Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201-07.
51. Bangalore S, Parkar S, Grossman E, Messerli FHA meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007; 100 (8): 1254–62
52. Czuriga I, Riecansky I, Bodnar J et al. Comparizion of the new cardioselective beta–blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc. Drug Ther 2003; 17 (3): 257–63.
53. Poirier L, Cleroux J, Nadeau A et al. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 2001; 19 (8): 1429–35.
54. Bakris Gl, Fonseca V, Katholi RE et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292: 2227–36.
55. Остроумова О.Д. Возможности применения высокоселективных β-адреноблокаторов у больных с сопутствующими заболеваниями. Рус. мед. журн. 2004; 12: 721–25.
56. Кукес В.Г., Остроумова О.Д., Батурина А.М., Зыкова А.А. β-Адреноблокаторы в лечении артериальной гипертонии у больных с сахарным диабетом: противопоказание или препараты выбора? Рус. мед. журн. 2002; 10: 446–9.

В.И.Подзолков, К.К.Осадчий